Rugen Holdings (Cayman) Limited

Organization

Grand Cayman, KY

Organizations

Please log in for detailed analytics

Patents Grantslast 30 patents

Information Patent Grant
Treatment of autism spectrum disorders, obsessive-compulsive disord...
- Patent number 11,752,155
- Issue date Sep 12, 2023
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMD...
- Patent number 11,136,328
- Issue date Oct 5, 2021
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Treatment of autism spectrum disorders, obsessive-compulsive disord...
- Patent number 11,000,526
- Issue date May 11, 2021
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMD...
- Patent number 10,584,127
- Issue date Mar 10, 2020
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
- Patent number 10,420,768
- Issue date Sep 24, 2019
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMD...
- Patent number 10,294,230
- Issue date May 21, 2019
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists
- Patent number 10,221,182
- Issue date Mar 5, 2019
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
- Patent number 10,030,026
- Issue date Jul 24, 2018
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
- Patent number 9,968,610
- Issue date May 15, 2018
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists
- Patent number 9,567,341
- Issue date Feb 14, 2017
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORD...
- Publication number 20240207273
- Publication date Jun 27, 2024
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...
- Publication number 20220024937
- Publication date Jan 27, 2022
- Rugen Holdings (Cayman) Limited
- Gideon SHAPIRO
- C07 - ORGANIC CHEMISTRY
Information Patent Application
TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORD...
- Publication number 20210220365
- Publication date Jul 22, 2021
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...
- Publication number 20200299300
- Publication date Sep 24, 2020
- Rugen Holdings (Cayman) Limited
- Gideon SHAPIRO
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORD...
- Publication number 20190298725
- Publication date Oct 3, 2019
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...
- Publication number 20180346476
- Publication date Dec 6, 2018
- Rugen Holdings (Cayman) Limited
- Gideon SHAPIRO
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
- Publication number 20180303834
- Publication date Oct 25, 2018
- Rugen Holdings (Cayman) Limited
- Gideon SHAPIRO
- C07 - ORGANIC CHEMISTRY
Information Patent Application
TREATMENT OF ANXIETY DISORDERS AND AUTISM SPECTRUM DISORDERS
- Publication number 20180271869
- Publication date Sep 27, 2018
- Rugen Holdings (Cayman) Limited
- Jie Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...
- Publication number 20180170935
- Publication date Jun 21, 2018
- Rugen Holdings (Cayman) Limited
- Gideon SHAPIRO
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
- Publication number 20180030055
- Publication date Feb 1, 2018
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- C07 - ORGANIC CHEMISTRY
Information Patent Application
PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
- Publication number 20170209449
- Publication date Jul 27, 2017
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
- Publication number 20170101412
- Publication date Apr 13, 2017
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- C07 - ORGANIC CHEMISTRY
Information Patent Application
PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
- Publication number 20160075713
- Publication date Mar 17, 2016
- Rugen Holdings (Cayman) Limited
- Gideon Shapiro
- C07 - ORGANIC CHEMISTRY

Rugen Holdings (Cayman) Limited

Organization

Patents Grantslast 30 patents

Treatment of autism spectrum disorders, obsessive-compulsive disord...

3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMD...

Treatment of autism spectrum disorders, obsessive-compulsive disord...

3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMD...

Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists

3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMD...

3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists

Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists

Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists

Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists

Patents Applicationslast 30 patents

TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORD...

3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...

TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORD...

3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...

TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORD...

3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...

PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

TREATMENT OF ANXIETY DISORDERS AND AUTISM SPECTRUM DISORDERS

3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMD...

3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

Trademarklast 30 trademarks